Suppr超能文献

医疗器械;医疗器械报告;基线报告。直接最终规则。

Medical devices; medical device reporting; baseline reports. Direct final rule.

出版信息

Fed Regist. 2008 Jun 13;73(115):33692-5.

Abstract

The Food and Drug Administration (FDA) is amending its medical device reporting regulations to remove a requirement for baseline reports that the agency deems no longer necessary. Currently, manufacturers provide baseline reports to FDA that include the FDA product code and the premarket approval or premarket notification number. Because most of the information in these baseline reports is also submitted to FDA in individual adverse event reports, FDA is removing the requirement for baseline reports. The removal of this requirement will eliminate unnecessary duplication and reduce the manufacturer's reporting burden. FDA is amending the regulation in accordance with its direct final rule procedures. Elsewhere in this issue of the Federal Register, we are publishing a companion proposed rule under FDA's usual procedures for notice and comment to provide a procedural framework to finalize the rule in the event we receive a significant adverse comment and withdraw this direct final rule.

摘要

美国食品药品监督管理局(FDA)正在修订其医疗器械报告法规,以取消一项该机构认为不再必要的基线报告要求。目前,制造商向FDA提供基线报告,其中包括FDA产品代码以及上市前批准或上市前通知编号。由于这些基线报告中的大部分信息也会在个体不良事件报告中提交给FDA,因此FDA正在取消对基线报告的要求。取消这一要求将消除不必要的重复,并减轻制造商的报告负担。FDA正在根据其直接最终规则程序修订该法规。在本期《联邦公报》的其他地方,我们正在根据FDA通常的通知和评论程序发布一项配套的拟议规则,以便在我们收到重大负面评论并撤回此直接最终规则的情况下,提供一个程序框架来最终确定该规则。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验